← Alchemist
EarningsSEC FilingsGuidance

What Did Agilent's Q2 2026 Earnings Release Say About Raised Guidance?

Agilent raised FY26 revenue guidance to $7.39B-$7.49B and non-GAAP EPS to $6.00-$6.10, citing strong Q2 results and operational momentum — see the exact filing language.

Agilent raised its full-year 2026 guidance after Q2 results, citing "continued operational momentum" — full-year revenue is now expected at $7.39–$7.49 billion and non-GAAP EPS at $6.00–$6.10, both increases from prior guidance.

What exact language did Agilent use to raise guidance?

Agilent's Q2 fiscal 2026 earnings release headline states the company "Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS guidance on continued operational momentum." That's the framing sentence — everything else in the release is the specific numbers behind it. Filings that raise guidance consistently pair a qualitative claim ("strong results," "operational momentum") with quantitative detail in the same paragraph, which is what makes the language checkable rather than promotional: a reader can verify the qualitative claim against the numbers that follow.

What were the actual numbers, before and after?

The release states: "Fiscal year 2026 revenue is now expected in the range of $7.39 billion to $7.49 billion, representing a range of up 6.3% to 7.8% reported and up 4.5% to 6.0% core, an increase of 30 basis points at the midpoint." On profitability: "Non-GAAP EPS is now expected in the range of $6.00 to $6.10, an increase of 8 cents at the midpoint." Both figures are stated as revisions — "now expected," "an increase of" — which is the tell that distinguishes a guidance raise from an initial guidance issuance. (Source: Agilent Q2 FY2026 earnings release, filed May 27, 2026.)

Does this pattern show up in other companies' filings?

Yes — the same "now expected," "previously," or "raising" construction appears across unrelated filings whenever a company revises guidance mid-year. Lowe's, in its Q3 2025 earnings release, stated its updated sales outlook as "$86.0 billion (previously $84.5 to $85.5 billion)" — the parenthetical prior-range citation is a second, equally common way to make a revision explicit. Bristol Myers Squibb's Q3 2025 release used "Raising 2025 revenue guidance to a range of ~$47.5 billion to $48.0 billion." Not every company raises guidance every quarter — McKesson's March 2026 announcement of its Q4 FY2026 earnings date instead "reaffirmed" its outlook "as previously issued," language that signals no change rather than a revision.

Q&A

What did Agilent say about its FY26 revenue guidance? Agilent raised FY26 revenue guidance to $7.39–$7.49 billion, an increase of 30 basis points at the midpoint from the prior range.

Did Agilent raise or lower non-GAAP EPS guidance? Raised — to $6.00–$6.10, an increase of 8 cents at the midpoint.

What's the difference between "raising guidance" and "reaffirming guidance" in a filing? Raising guidance revises a previously stated range upward, usually with "now expected" or "previously" language showing the old and new figures. Reaffirming guidance restates the existing range unchanged, signaling no new information rather than a revision.

Is a guidance raise always framed with a specific dollar or percentage figure? In the examples here, yes — every raise cited a specific new range and, in Agilent's and Lowe's cases, an explicit comparison to the prior range or midpoint change.

Where does this guidance language come from? Directly from each company's SEC filing (8-K exhibit or earnings release), not from a summary or analyst commentary — every quote above is verbatim from the filing itself.

Ready to explore structured financial intelligence?

Start Exploring →